MAS broadens scope of Major Payment Institution license for blockchain firm's subsidiaryMAS broadens scope of Major Payment Institution license for blockchain firm's subsidiary

Ripple Receives Approval to Expand Payment Services in Singapore

Ripple Receives Approval to Expand Payment Services in Singapore

Ripple has received approval from Singapore's Monetary Authority to expand the scope of payment activities under the Major Payment Institution (MPI) license held by its local subsidiary, Ripple Markets APAC, the company announced today in a statement.

The expanded license allows Ripple to broaden its regulated payment offerings in Singapore, including services involving digital payment tokens such as its newly launched RLUSD stablecoin and XRP. The company's Singapore entity is among the few blockchain-enabled institutions globally holding an MPI license.

"MAS has set a leading standard for regulatory clarity in digital assets, and we deeply value Singapore's forward-thinking approach," said Monica Long, Ripple's president. "This expanded license strengthens our ability to continue investing in Singapore and to build the infrastructure financial institutions need to move money efficiently, quickly, and safely."

Ripple's payment platform combines digital payment tokens with a global payout network to facilitate cross-border transactions for banks, crypto companies, and fintechs. The service handles blockchain infrastructure and operational complexity, allowing businesses to launch digital payment services without building their own systems.

The expanded scope enables Ripple to offer end-to-end payment solutions including collection, holding, token swapping, and payout services through a single integration point. Customers can access digital payment tokens without maintaining specialized infrastructure or additional banking relationships, the company said.

"The Asia Pacific region leads the world in real digital asset usage, with on-chain activity up roughly 70% year-over-year. Singapore sits at the center of that growth," said Fiona Murray, Ripple's vice president and managing director for Asia Pacific. "With this expanded scope of payment activities, we can better support the institutions driving that growth."

Ripple established its Asia Pacific headquarters in Singapore in 2017. The MAS has positioned itself as a regulatory leader in digital assets, implementing frameworks including the Payment Services Act that governs stablecoin issuance and crypto service providers.

➢ Stay ahead of the curve. Join Blockhead on Telegram today for all the latest in crypto.
+ Follow Blockhead on Google News
Market Opportunity
Massa Logo
Massa Price(MAS)
$0.00491
$0.00491$0.00491
+0.20%
USD
Massa (MAS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26